Image Sourced Shutterstock
Market Herald logo


Be the first with the news that moves the market
  • Medicinal cannabis developers Althea had a record month of patients prescribed with its products in July
  • The company has also entered an agreement with medicinal cannabis online education hub Tetra Health. The agreement will distribute and educate doctors and patients on Althea’s products
  • Althea’s share price is up 4.12 per cent today, currently sitting at $1.01 per share

Medicinal cannabis developers Althea had a record month of patients prescribed its products in July.

A total of 1523 patients have now been treated with Althea’s medical-grade hemp by 245 health professionals in Australia.

According to the company, July saw 334 new patients prescribed, equating to over 14 new patients per business day.

Early reports show throughout August sales are further increasing.

The company entered a partnership with Tetra Health, an organisation which directs patients and physicians to obtain safe and legal medicinal cannabis.

The partnership is intended to assist the growth of Althea’s products across the country.

CEO at Althea Josh Fegan said: “We are very pleased to have achieved a record-breaking month in July and entered into and agreement with Tetra Health, one of the leading medicinal cannabis related service providers in Australia.”

“This agreement gives us access to a wider network of health care practitioners as we continue on our mission of being the leading provider of high quality medicinal cannabis products to patients in Australia,” Josh added.

The agreement will see Tetra exclusively educate on and distribute Althea’s products to doctors and patients. The online education hub is sponsored by Althea and has seen 500 per cent growth in eligible users on the site last month.

Althea has a dedicated team which works on implementing the company’s own technology aimed reducing the application time for health professionals looking to prescribe medicinal hemp.

The Australian medicinal hemp market has reached its highest point as government bodies, the Therapeutic Goods Administration and Special Access Scheme Category B, increase their approvals.

Althea’s share price is up 4.12 per cent today, currently sitting at $1.01 per share.

AGH by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.